Last 12 months
Inside the activity.
0 purchase rows · 30 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 18 |
| Sep 2026 | 0 | 12 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 18:21 UTC |
Twitty ChristopherChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023356 · wk-form4_1775168465.xml · derivative · entry 7 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-10-28 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F6 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:21 UTC |
Twitty ChristopherChief Scientific Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 7,100 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023356 · wk-form4_1775168465.xml · derivative · entry 6 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,100 shares Expires 2033-11-06 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:21 UTC |
Twitty ChristopherChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 7,100 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023356 · wk-form4_1775168465.xml · derivative · entry 5 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,100 Underlying: Common Stock · 7,100 shares Expires 2033-11-06 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:21 UTC |
Twitty ChristopherChief Scientific Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $14.56 | Not disclosed |
DisclosureSEC source: 0001628280-26-023356 · wk-form4_1775168465.xml · derivative · entry 4 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2034-02-28 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:21 UTC |
Twitty ChristopherChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $0.61 | Not disclosed |
DisclosureSEC source: 0001628280-26-023356 · wk-form4_1775168465.xml · derivative · entry 3 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-02-28 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:21 UTC |
Twitty ChristopherChief Scientific Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 17,004 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023356 · wk-form4_1775168465.xml · derivative · entry 2 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,004 shares Expires 2033-09-29 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:21 UTC |
Twitty ChristopherChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 17,004 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023356 · wk-form4_1775168465.xml · derivative · entry 1 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,004 Underlying: Common Stock · 17,004 shares Expires 2033-09-29 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:15 UTC |
Grayson Paul A.Director
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001628280-26-023346 · wk-form4_1775168112.xml · derivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 21,586 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 14 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,586 shares Expires 2033-09-29 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 21,586 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 13 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,586 Underlying: Common Stock · 21,586 shares Expires 2033-09-29 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 9,013 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 12 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,013 shares Expires 2033-11-06 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F6 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 9,013 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 11 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,013 Underlying: Common Stock · 9,013 shares Expires 2033-11-06 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F6 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $14.56 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 10 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 9 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 650,000 | Not disclosed Strike: $5.15 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 8 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650,000 shares Expires 2034-10-27 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 650,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 7 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2034-10-27 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 12,360 | Not disclosed Strike: $14.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 6 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,360 shares Expires 2031-12-14 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 12,360 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 5 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,360 Underlying: Common Stock · 12,360 shares Expires 2031-12-14 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 36,000 | Not disclosed Strike: $11.25 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 4 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2030-08-07 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 36,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 3 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2030-08-07 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $2.89 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2035-02-25 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-02-25 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:22 UTC |
Smith Karen L.Director
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001628280-26-023358 · wk-form4_1775168549.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:20 UTC |
Jenkins AnnalisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001628280-26-023354 · wk-form4_1775168412.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:17 UTC |
Charych Deborah H.Director
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001628280-26-023349 · wk-form4_1775168222.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:13 UTC |
Schwab Andrew J.Director
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001628280-26-023343 · wk-form4_1775167994.xml · derivative · entry 1 Schwab Andrew J. · CIK 0001598549 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC |
Arora Puneet S.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006619 · wk-form4_1770688454.xml · derivative · entry 1 Arora Puneet S. · CIK 0002035933 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC |
Diep Tuan TuChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006620 · wk-form4_1770688461.xml · derivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC |
ARSENAULT KAITLYNChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006624 · wk-form4_1770688482.xml · derivative · entry 1 ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC |
Twitty ChristopherChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006623 · wk-form4_1770688476.xml · derivative · entry 1 Twitty Christopher · CIK 0001870121 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC |
Grayson Paul A.Director
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006626 · wk-form4_1770688493.xml · derivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 01:54 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006618 · wk-form4_1770688448.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:06 UTC |
Schwab Andrew J.Director
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006631 · wk-form4_1770689187.xml · derivative · entry 1 Schwab Andrew J. · CIK 0001598549 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 01:54 UTC |
Smith Karen L.Director
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006625 · wk-form4_1770688487.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 01:54 UTC |
Charych Deborah H.Director
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006622 · wk-form4_1770688470.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 01:54 UTC |
Jenkins AnnalisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006621 · wk-form4_1770688465.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 23:05 UTC |
5AM Partners VII, LLC10% owner
5AM Ventures VII, L.P.10% owner
5AM Partners II, LLC10% owner
5AM Ventures II LP10% owner
5AM CO-INVESTORS II LP10% owner
DIEKMAN JOHN D10% owner
PARMAR KUSH10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 6,470 | $3.42 | $22,127.40 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 4 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 57,493 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 23:05 UTC |
5AM Partners VII, LLC10% owner
5AM Ventures VII, L.P.10% owner
5AM Partners II, LLC10% owner
5AM Ventures II LP10% owner
5AM CO-INVESTORS II LP10% owner
DIEKMAN JOHN D10% owner
PARMAR KUSH10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 163,979 | $3.42 | $560,808.18 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 3 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,457,064 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 23:07 UTC |
Schwab Andrew J.Director · 10% owner
|
SaleCommon Stock | 6,470 | $3.42 | $22,127.40 |
DisclosureSEC source: 0001415889-25-022808 · form4-08222025_110825.xml · nonDerivative · entry 4 Schwab Andrew J. · CIK 0001598549 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 57,493 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 23:07 UTC |
Schwab Andrew J.Director · 10% owner
|
SaleCommon Stock | 163,979 | $3.42 | $560,808.18 |
DisclosureSEC source: 0001415889-25-022808 · form4-08222025_110825.xml · nonDerivative · entry 3 Schwab Andrew J. · CIK 0001598549 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,457,064 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 23:05 UTC |
5AM Partners VII, LLC10% owner
5AM Ventures VII, L.P.10% owner
5AM Partners II, LLC10% owner
5AM Ventures II LP10% owner
5AM CO-INVESTORS II LP10% owner
DIEKMAN JOHN D10% owner
PARMAR KUSH10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 2,314 | $3.57 | $8,260.98 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 2 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 63,963 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 23:05 UTC |
5AM Partners VII, LLC10% owner
5AM Ventures VII, L.P.10% owner
5AM Partners II, LLC10% owner
5AM Ventures II LP10% owner
5AM CO-INVESTORS II LP10% owner
DIEKMAN JOHN D10% owner
PARMAR KUSH10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 58,642 | $3.57 | $209,351.94 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,621,043 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 23:07 UTC |
Schwab Andrew J.Director · 10% owner
|
SaleCommon Stock | 2,314 | $3.57 | $8,260.98 |
DisclosureSEC source: 0001415889-25-022808 · form4-08222025_110825.xml · nonDerivative · entry 2 Schwab Andrew J. · CIK 0001598549 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 63,963 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 23:07 UTC |
Schwab Andrew J.Director · 10% owner
|
SaleCommon Stock | 58,642 | $3.57 | $209,351.94 |
DisclosureSEC source: 0001415889-25-022808 · form4-08222025_110825.xml · nonDerivative · entry 1 Schwab Andrew J. · CIK 0001598549 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,621,043 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 17:34 UTC |
Arora Puneet S.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000004 · wk-form4_1740609251.xml · derivative · entry 1 Arora Puneet S. · CIK 0002035933 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests 25% on the one year anniversary of February 21, 2025 and 1/48th monthly thereafter. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 17:38 UTC |
Diep Tuan TuChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000006 · wk-form4_1740609481.xml · derivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 17:53 UTC |
ARSENAULT KAITLYNChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000018 · wk-form4_1740610387.xml · derivative · entry 1 ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 17:47 UTC |
Grayson Paul A.Director
|
GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000014 · wk-form4_1740610053.xml · derivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:43 UTC |
DHILLON PUNITDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000010 · wk-form4_1740609817.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 00:45 UTC |
Schwab Andrew J.Director
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000020 · wk-form4_1740617150.xml · derivative · entry 1 Schwab Andrew J. · CIK 0001598549 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.